Cisplatin nephrotoxicity: experimental and clinical studies.

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Background:

• Cisplatin is a vital chemotherapy agent for various cancers, including germ cell tumors.
• Nephrotoxicity is a significant dose-limiting side effect of cisplatin treatment.
• Understanding the mechanisms of cisplatin-induced kidney damage is crucial for patient management.

Purpose of the Study:

• To elucidate the pathophysiological mechanisms underlying cisplatin-induced nephrotoxicity.
• To investigate the temporal relationship between tubular function, renal hemodynamics, and cisplatin dosage.
• To assess the long-term renal effects of cisplatin in human patients.

Main Methods:

• Animal studies (dogs and rats) involving cisplatin administration to measure renal blood flow (RBF), glomerular filtration rate (GFR), and tubular reabsorption.
• Human clinical study with different cisplatin dosage regimens (20 mg/m²/day and 40 mg/m²/day for 5 days).
• Monitoring of renal function markers including 51Cr-EDTA clearance, N-acetyl-beta-D-glucosaminidase, beta-2-microglobulin, and proteinuria.

Main Results:

• Cisplatin acutely impairs proximal tubular reabsorption in dogs and rats before affecting renal hemodynamics.
• High-dose cisplatin in humans causes progressive GFR decline, persistent tubular dysfunction, and proteinuria.
• Renal function markers indicate primary tubular damage, with effects lasting for months to years post-treatment.

Conclusions:

• Cisplatin-induced nephrotoxicity initiates with proximal tubular impairment, followed by hemodynamic changes.
• High-dose cisplatin leads to severe, prolonged renal dysfunction, affecting both tubular and glomerular components.
• Further research is needed to develop strategies for reducing cisplatin's renal toxicity.